Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 172

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Durable responses to imatinib in patients with PDGFRB fusion gene–positive and BCR-ABL–negative chronic myeloproliferative disorders

Open access
David, Marianna, Cross, Nicholas C. P., Burgstaller, Sonja, Chase, Andrew, Curtis, Claire, Dang, Raymond, Gardembas, Martine, Goldman, John M., Grand, Francis, Hughes, George, Huguet, Francoise, Lavender, Louise, McArthur, Grant A., Mahon, Francois X., Massimini, Giorgio, Melo, Junia, Rousselot, Philippe, Russell-Jones, Robin J., Seymour, John F., Smith, Graeme, Stark, Alastair, Waghorn, Katherine, Nikolova, Zariana, Apperley, Jane F. · 2007 · Blood

Abstract

Fusion genes derived from the platelet-derived growth factor receptor beta (PDGFRB) or alpha (PDGFRA) play an important role in the pathogenesis of BCR-ABL–negative chronic myeloproliferative disorders (CMPDs). These fusion genes encode constitutively activated receptor tyrosine kinases that can be inhibited by imatinib. Twelve patients with BCR-ABL–negative CMPDs and reciprocal translocations involving PDGFRB received imatinib for a median of 47 months (range, 0.1-60 months). Eleven had prompt responses with normalization of peripheral-blood cell counts and disappearance of eosinophilia; 10 had complete resolution of cytogenetic abnormalities and decrease or disappearance of fusion transcripts as measured by reverse transcriptase–polymerase chain reaction (RT-PCR). Updates were sought from 8 further patients previously described in the literature; prompt responses were described in 7 and persist in 6. Our data show that durable hematologic and cytogenetic responses are achieved with imatinib in patients with PDGFRB fusion–positive, BCR-ABL–negative CMPDs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2006-05-024828

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 172

Metadata

Authors
David, M., Cross, N. C. P., Burgstaller, S., Chase, A., Curtis, C., Dang, R., Gardembas, M., Goldman, J. M., Grand, F., Hughes, G., Huguet, F., Lavender, L., McArthur, G. A., Mahon, F. X., Massimini, G., Melo, J., Rousselot, P., Russell-Jones, R. J., Seymour, J. F., Smith, G., Stark, A., Waghorn, K., Nikolova, Z., & Apperley, J. F.
Venue
Blood
Published
2006-09-07
Volume
109
Issue
1
Pages
61-64
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2075213943
Cited by
172
References
1
FWCI
5.54
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Durable responses to imatinib in patients with PDGFRB fusion gene–positive and BCR-ABL–negative chronic myeloproliferative disorders. https://app.cochat.ai/papers/10.1182/blood-2006-05-024828
The paper
David, M., Cross, N. C. P., Burgstaller, S., Chase, A., Curtis, C., Dang, R., Gardembas, M., Goldman, J. M., Grand, F., Hughes, G., Huguet, F., Lavender, L., McArthur, G. A., Mahon, F. X., Massimini, G., Melo, J., Rousselot, P., Russell-Jones, R. J., Seymour, J. F., . . . Apperley, J. F. (2007). Durable responses to imatinib in patients with PDGFRB fusion gene–positive and BCR-ABL–negative chronic myeloproliferative disorders. Blood. https://doi.org/10.1182/blood-2006-05-024828

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.